Understanding the disease: euglycemic ketoacidosis with SGLT2 inhibitors
- 3 February 2025
- journal article
- understanding the-disease
- Published by Springer Nature in Intensive Care Medicine
- Vol. 51 (4) , 779-782
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- How to manage sodium-glucose cotransporter-2 inhibitors in the critically ill patient?Intensive Care Medicine, 2024
- Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trialsCurrent Problems in Cardiology, 2024
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Correction to: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2023
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2022
- The management of diabetic ketoacidosis in adults—An updated guideline from the Joint British Diabetes Society for Inpatient CareDiabetic Medicine, 2022
- SGLT‐2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions databaseFundamental & Clinical Pharmacology, 2017
- Electrolyte Disturbances in Patients with Chronic Alcohol-Use DisorderNew England Journal of Medicine, 2017
- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 InhibitorNew England Journal of Medicine, 2017
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretionNature Medicine, 2015